Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.84 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | THPO | P40225 | 1/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9765879 | 0.92 | ADORA2B (0.85) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL9765918 | 0.92 | ADORA2B (0.85) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL14564546 | 0.88 | ADORA2B (0.79) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL1321894 | 0.88 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL24304504 | 0.87 | ADORA2B (0.76) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7318202 | 0.87 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL1948455 | 0.87 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL1065789 | 0.85 | ADORA2B (0.73) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL7313540 | 0.85 | ADORA2B (0.78) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL3464940 | 0.84 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | claimed |
| EP-3876871-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | The Regents of the University of California (US) | 2021-09-15 | — | — | EP | claimed |
| WO-2014055932-A1 | INTEGRATED NEUROMODULATION SYSTEM FOR MOOD ENHANCEMENT OF A LIVING HUMAN SUBJECT | INVIVO BEVERAGES LLC (US) | 2014-04-10 | — | — | WO | claimed |
| US-8609162-B2 | Integrated neuromodulation system for mood enhancement of a living human subject | INVIVO BEVERAGES LLC (US) | 2013-12-17 | — | — | US | claimed |
| US-20130156872-A1 | Integrated Neuromodulation System for Mood Enhancement of a Living Human Subject | INVIVO BEVERAGES LLC (US) | 2013-06-20 | — | — | US | claimed |
| US-20110262442-A1 | COMPOSITIONS FOR TREATING CNS DISORDERS | ADENIOS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| WO-2011057199-A1 | COMPOSITIONS FOR TREATING CNS DISORDERS | ADENIOS, INC. (US) | 2011-05-12 | — | — | WO | claimed |
| US-6555545-B2 | Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents | NEW YORK UNIVERSITY | 2003-04-29 | — | — | US | claimed |
| EP-1272897-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001058241-A9 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | UNIV NEW YORK (US) | 2002-10-17 | — | — | WO | claimed |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | NEW YORK UNIVERSITY | 2002-01-03 | — | — | US | claimed |
| WO-2001058241-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2001-08-16 | — | — | WO | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | claimed |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | HALOZYME HYPERCON, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12558323-B2 | Particle formation and morphology | ELEKTROFI, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-4612315-A | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1986-09-16 | — | — | US | disclosed |
| US-4612315-A | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1986-09-16 | — | — | US | disclosed |
| US-4593095-A | ADENOSINE RECEPTOR ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ALB, S100P, S100A8 | ADORA2B 3145/4885ADORA2A 2833/4885KDM4E 3147/4885 |
| US-12558323-B2 | Particle formation and morphology | CD63, EXOSC10, EPCAM | ADORA2B 4009/4885ADORA2A 3001/4885KDM4E 2657/4885 |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | ADORA2A, ADORA1, ADORA2B | ADORA2B 3/4885ADORA2A 1/4885KDM4E 2470/4885 |
| US-20210393857-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | PER2, NCOR2, NR4A2 | ADORA2B 672/4885ADORA2A 254/4885KDM4E 1437/4885 |
| US-20130156872-A1 | Integrated Neuromodulation System for Mood Enhancement of a Living Human Subject | BDNF, SLC18A2, HTR5A | ADORA2B 320/4885ADORA2A 128/4885KDM4E 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.